Document Detail


Vinpocetine inhibits oligodendroglial precursor cell differentiation.
MedLine Citation:
PMID:  22854710     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In multiple sclerosis during periods of remission a limited degree of myelin repair can be observed mediated by oligodendroglial precursor cells. Phosphodiesterase inhibitors act as anti-inflammatory agents and might hold promise for future multiple sclerosis treatment.
AIMS: To investigate whether phosphodiesterase inhibitors could also influence myelin repair.
METHODS: We stimulated primary oligodendroglial precursor cells with cilostazol, rolipram and vinpocetine and assessed their effects on repair related cellular processes.
RESULTS: We found that vinpocetine exerted a strong negative effect on myelin expression while cilostazol and rolipram did not show such effects. In addition, vinpocetine decreased morphological complexities suggesting an overall negative impact on oligodendroglial cell maturation. We provide evidence that this is not mediated via a blockade of phosphodiesterase-1 but rather by inhibition of IĸB kinase.
CONCLUSION: These findings suggest that vinpocetine via IĸB inhibition exerts a strong negative impact on oligodendroglial cell maturation and may therefore provide the rationale to restrict its application during periods of remission in multiple sclerosis patients. This is of particular interest since vinpocetine is widely used as a health supplement thought to act as a cognitive and memory enhancer for healthy people and patients with neurological or muscle diseases.
Authors:
Klintsy Julieta Torres; Peter Göttle; David Kremer; Jose Flores Rivera; Lucinda Aguirre-Cruz; Teresa Corona; Hans-Peter Hartung; Patrick Küry
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-08-01
Journal Detail:
Title:  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology     Volume:  30     ISSN:  1421-9778     ISO Abbreviation:  Cell. Physiol. Biochem.     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-14     Completed Date:  2012-12-13     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  9113221     Medline TA:  Cell Physiol Biochem     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  711-22     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Heinrich-Heine-University, Medical Faculty, Department of Neurology, Düsseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Differentiation / drug effects*
Cells, Cultured
Chemokine CXCL12 / metabolism
Gene Expression Regulation / drug effects
I-kappa B Kinase / metabolism
Myelin Sheath / genetics,  metabolism
Oligodendroglia / cytology,  metabolism*
Phosphodiesterase Inhibitors / pharmacology*
Rats
Rolipram / pharmacology
Tetrazoles / pharmacology
Vinca Alkaloids / pharmacology*
Chemical
Reg. No./Substance:
0/Chemokine CXCL12; 0/Phosphodiesterase Inhibitors; 0/Tetrazoles; 0/Vinca Alkaloids; 543512OBTC/vinpocetine; 61413-54-5/Rolipram; EC 2.7.11.10/I-kappa B Kinase; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis.
Next Document:  Four polymorphisms of cholesteryl ester transfer protein gene and coronary stenosis in a Tunisian po...